

Audra L Stinchcomb

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1108891/publications.pdf>

Version: 2024-02-01

93
papers

3,458
citations

147801

31
h-index

155660

55
g-index

97
all docs

97
docs citations

97
times ranked

3372
citing authors

#	ARTICLE	IF	CITATIONS
1	Evaluation of in vitro/in vivo correlations for three fentanyl transdermal delivery systems using in vitro skin permeation testing and human pharmacokinetic studies under the influence of transient heat application. <i>Journal of Controlled Release</i> , 2022, 342, 134-147.	9.9	9
2	Investigator Impact on Reproducibility of Drug Bioavailability in Stratum Corneum Sampling by Tape Stripping. <i>Pharmaceutical Research</i> , 2022, 39, 703.	3.5	0
3	Understanding Formulation and Temperature Effects on Dermal Transport Kinetics by IVPT and Multiphysics Simulation. <i>Pharmaceutical Research</i> , 2022, 39, 893-905.	3.5	3
4	Cutaneous Pharmacokinetics of Acyclovir Cream 5% Products: Evaluating Bioequivalence with an In Vitro Permeation Test and an Adaptation of Scaled Average Bioequivalence. <i>Pharmaceutical Research</i> , 2020, 37, 210.	3.5	14
5	Effect of Controlled Heat Application on Topical Diclofenac Formulations Evaluated by In Vitro Permeation Tests (IVPT) Using Porcine and Human Skin. <i>Pharmaceutical Research</i> , 2020, 37, 49.	3.5	6
6	Unique treatment potential of cannabidiol for the prevention of relapse to drug use: preclinical proof of principle. <i>Neuropsychopharmacology</i> , 2018, 43, 2036-2045.	5.4	106
7	In vitro “in vivo correlations for nicotine transdermal delivery systems evaluated by both in vitro skin permeation (IVPT) and in vivo serum pharmacokinetics under the influence of transient heat application. <i>Journal of Controlled Release</i> , 2018, 270, 76-88.	9.9	32
8	Minimally invasive technique for measuring transdermal glucose with a fluorescent biosensor. <i>Analytical and Bioanalytical Chemistry</i> , 2018, 410, 7249-7260.	3.7	16
9	The Sensitivity of In Vitro Permeation Tests to Chemical Penetration Enhancer Concentration Changes in Fentanyl Transdermal Delivery Systems. <i>AAPS PharmSciTech</i> , 2018, 19, 2778-2786.	3.3	10
10	Microneedle-Assisted Skin Permeation by Nontoxic Bioengineerable Gas Vesicle Nanoparticles. <i>Molecular Pharmaceutics</i> , 2017, 14, 953-958.	4.6	18
11	Measuring transdermal glucose levels in neonates by passive diffusion: an in vitro porcine skin model. <i>Analytical and Bioanalytical Chemistry</i> , 2017, 409, 3475-3482.	3.7	6
12	On the Road to Development of an in Vitro Permeation Test (IVPT) Model to Compare Heat Effects on Transdermal Delivery Systems: Exploratory Studies with Nicotine and Fentanyl. <i>Pharmaceutical Research</i> , 2017, 34, 1817-1830.	3.5	22
13	LC-MS determination of fentanyl in human serum and application to a fentanyl transdermal delivery pharmacokinetic study. <i>Bioanalysis</i> , 2017, 9, 1551-1560.	1.5	6
14	Binge Alcohol Exposure Transiently Changes the Endocannabinoid System: A Potential Target to Prevent Alcohol-Induced Neurodegeneration. <i>Brain Sciences</i> , 2017, 7, 158.	2.3	7
15	Transdermal cannabidiol reduces inflammation and pain-related behaviours in a rat model of arthritis. <i>European Journal of Pain</i> , 2016, 20, 936-948.	2.8	205
16	A fully validated LC-MS/MS method for simultaneous determination of nicotine and its metabolite cotinine in human serum and its application to a pharmacokinetic study after using nicotine transdermal delivery systems with standard heat application in adult smokers. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2016, 1020, 67-77.	2.3	32
17	Norelgestromin/ethinyl estradiol intravenous infusion formulation optimization, stability and compatibility testing: A case study to overcome polysorbate 80 interference in chromatographic analysis. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2016, 125, 145-153.	2.8	5
18	Programmable Transdermal Clonidine Delivery Through Voltage-Gated Carbon Nanotube Membranes. <i>Journal of Pharmaceutical Sciences</i> , 2014, 103, 1829-1838.	3.3	10

#	ARTICLE	IF	CITATIONS
19	Optimization of Naltrexone Diclofenac Codrugs for Sustained Drug Delivery Across Microneedle-Treated Skin. <i>Pharmaceutical Research</i> , 2014, 31, 148-159.	3.5	8
20	Synthesis and in vitro stability of amino acid prodrugs of 6- β -naltrexol for microneedle-enhanced transdermal delivery. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2014, 24, 5212-5215.	2.2	7
21	Quantification of anandamide, oleoylethanolamide and palmitoylethanolamide in rodent brain tissue using high performance liquid chromatography-electrospray mass spectroscopy. <i>Journal of Pharmaceutical Analysis</i> , 2014, 4, 234-241.	5.3	23
22	Fluvastatin as a Micropore Lifetime Enhancer for Sustained Delivery Across Microneedle-Treated Skin. <i>Journal of Pharmaceutical Sciences</i> , 2014, 103, 652-660.	3.3	25
23	Diclofenac Enables Unprecedented Week-Long Microneedle-Enhanced Delivery of a Skin Impermeable Medication in Humans. <i>Pharmaceutical Research</i> , 2013, 30, 1947-1955.	3.5	38
24	Annette Bunge: Developing the Principles in Percutaneous Absorption Using Chemical Engineering Principles. <i>Skin Pharmacology and Physiology</i> , 2013, 26, 313-316.	2.5	0
25	Transdermal delivery of cannabidiol attenuates binge alcohol-induced neurodegeneration in a rodent model of an alcohol use disorder. <i>Pharmacology Biochemistry and Behavior</i> , 2013, 111, 120-127.	2.9	46
26	Microneedle-Assisted Percutaneous Delivery of Naltrexone Hydrochloride in Yucatan Minipig: In Vitro-In Vivo Correlation. <i>Molecular Pharmaceutics</i> , 2013, 10, 3745-3757.	4.6	21
27	Development of a Codrug Approach for Sustained Drug Delivery Across Microneedle-Treated Skin. <i>Journal of Pharmaceutical Sciences</i> , 2013, 102, 1458-1467.	3.3	20
28	Effect of Formulation pH on Transport of Naltrexone Species and Pore Closure in Microneedle-Enhanced Transdermal Drug Delivery. <i>Molecular Pharmaceutics</i> , 2013, 10, 2331-2339.	4.6	15
29	Pharmacokinetic and Pharmacodynamic Profile of Supratherapeutic Oral Doses of Δ^9 -THC in Cannabis Users. <i>Journal of Clinical Pharmacology</i> , 2013, 53, 680-690.	2.0	30
30	Development of In Vivo Impedance Spectroscopy Techniques for Measurement of Micropore Formation Following Microneedle Insertion. <i>Journal of Pharmaceutical Sciences</i> , 2013, 102, 1948-1956.	3.3	9
31	Estimation of Maximum Transdermal Flux of Nonionized Xenobiotics from Basic Physicochemical Determinants. <i>Molecular Pharmaceutics</i> , 2012, 9, 2111-2120.	4.6	26
32	Diclofenac delays micropore closure following microneedle treatment in human subjects. <i>Journal of Controlled Release</i> , 2012, 163, 220-229.	9.9	60
33	Naltrexone Salt Selection for Enhanced Transdermal Permeation Through Microneedle-Treated Skin. <i>Journal of Pharmaceutical Sciences</i> , 2012, 101, 2777-2786.	3.3	11
34	Programmable transdermal delivery of nicotine in hairless guinea pigs using carbon nanotube membrane pumps. <i>Journal of Pharmaceutical Sciences</i> , 2012, 101, 3823-3832.	3.3	11
35	Vehicle Composition Influence on the Microneedle-Enhanced Transdermal Flux of Naltrexone Hydrochloride. <i>Pharmaceutical Research</i> , 2011, 28, 124-134.	3.5	38
36	Diclofenac Enables Prolonged Delivery of Naltrexone Through Microneedle-Treated Skin. <i>Pharmaceutical Research</i> , 2011, 28, 1211-1219.	3.5	47

#	ARTICLE	IF	CITATIONS
37	Human skin permeation of δ^9 -tetrahydrocannabinol, cannabidiol and cannabinol. <i>Journal of Pharmacy and Pharmacology</i> , 2010, 56, 291-297.	2.4	87
38	Permeation of WIN 55,212-2, a potent cannabinoid receptor agonist, across human tracheo-bronchial tissue in vitro and rat nasal epithelium in vivo. <i>Journal of Pharmacy and Pharmacology</i> , 2010, 58, 1459-1465.	2.4	14
39	LC-MS Method for the Pharmacokinetic Evaluation of 2-Arachidonoyl Glycerol in Small Volume Plasma Samples. <i>Chromatographia</i> , 2010, 71, 65-70.	1.3	6
40	In vitro permeation of a pegylated naltrexone prodrug across microneedle-treated skin. <i>Journal of Controlled Release</i> , 2010, 146, 37-44.	9.9	48
41	The Role of Entrepreneurial Activities in Academic Pharmaceutical Science Research. <i>Journal of Pharmaceutical Sciences</i> , 2010, 99, 2532-2537.	3.3	4
42	Transdermal Delivery of Naltrexol and Skin Permeability Lifetime after Microneedle Treatment in Hairless Guinea Pigs. <i>Journal of Pharmaceutical Sciences</i> , 2010, 99, 3072-3080.	3.3	54
43	Novel 3-O-pegylated carboxylate and 3-O-pegylated carbamate prodrugs of naltrexone for microneedle-enhanced transdermal delivery. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2010, 20, 3280-3283.	2.2	12
44	Challenges and opportunities in dermal/transdermal delivery. <i>Therapeutic Delivery</i> , 2010, 1, 109-131.	2.2	428
45	Current aspects of formulation efforts and pore lifetime related to microneedle treatment of skin. <i>Expert Opinion on Drug Delivery</i> , 2010, 7, 617-629.	5.0	56
46	Cannabidiol bioavailability after nasal and transdermal application: effect of permeation enhancers. <i>Drug Development and Industrial Pharmacy</i> , 2010, 36, 1088-1097.	2.0	95
47	Towards mimicking natural protein channels with aligned carbon nanotube membranes for active drug delivery. <i>Life Sciences</i> , 2010, 86, 563-568.	4.3	38
48	Programmable transdermal drug delivery of nicotine using carbon nanotube membranes. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 11698-11702.	7.1	120
49	Transdermal Delivery of Bupropion and its Active Metabolite, Hydroxybupropion: A Prodrug Strategy as an Alternative Approach. <i>Journal of Pharmaceutical Sciences</i> , 2009, 98, 583-594.	3.3	25
50	Human Skin Permeation of 3-O-Alkyl Carbamate Prodrugs of Naltrexone. <i>Journal of Pharmaceutical Sciences</i> , 2009, 98, 2611-2625.	3.3	13
51	Simultaneous Quantification of Anandamide and Other Endocannabinoids in Dorsal Vagal Complex of Rat Brainstem by LC-MS. <i>Chromatographia</i> , 2009, 69, 1-7.	1.3	24
52	In Vitro Skin Diffusion Study of Pure Forskolin versus a Forskolin-Containing <i>Plectranthus barbatus</i> Root Extract. <i>Journal of Natural Products</i> , 2009, 72, 769-771.	3.0	13
53	Carbon Nanotube Membranes for use in the Transdermal Treatment of Nicotine Addiction and Opioid Withdrawal Symptoms. <i>Substance Abuse: Research and Treatment</i> , 2009, 3, SART.S1050.	0.9	6
54	Development of Opioid Transdermal Delivery Systems. , 2009, , 709-728.		0

#	ARTICLE	IF	CITATIONS
55	Flux Across of Microneedle-treated Skin is Increased by Increasing Charge of Naltrexone and Naltrexol In Vitro. <i>Pharmaceutical Research</i> , 2008, 25, 1677-1685.	3.5	52
56	In vivo evaluation of a transdermal codrug of 6- β -naltrexol linked to hydroxybupropion in hairless guinea pigs. <i>European Journal of Pharmaceutical Sciences</i> , 2008, 33, 371-379.	4.0	20
57	Prodrugs and codrugs as strategies for improving percutaneous absorption. <i>Expert Review of Dermatology</i> , 2008, 3, 221-233.	0.3	7
58	Microneedles permit transdermal delivery of a skin-impermeant medication to humans. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008, 105, 2058-2063.	7.1	248
59	Intranasal absorption of δ^9 -tetrahydrocannabinol and WIN55,212-2 mesylate in rats. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2007, 65, 247-252.	4.3	17
60	Inhibition of calpain-mediated cell death by a novel peptide inhibitor. <i>Experimental Neurology</i> , 2006, 202, 506-513.	4.1	9
61	Synthesis and hydrolytic behavior of two novel tripartate codrugs of naltrexone and 6- β -naltrexol with hydroxybupropion as potential alcohol abuse and smoking cessation agents. <i>Bioorganic and Medicinal Chemistry</i> , 2006, 14, 7051-7061.	3.0	36
62	Near Infrared Spectrometry for the Quantification of Human Dermal Absorption of Econazole Nitrate and Estradiol. <i>Pharmaceutical Research</i> , 2006, 24, 186-193.	3.5	13
63	Near-Infrared Spectrometry for the Quantification of Dermal Absorption of Econazole Nitrate and 4-Cyanophenol. <i>Pharmaceutical Research</i> , 2006, 23, 835-843.	3.5	20
64	Enhancement of transdermal delivery of 6- β -naltrexol via a codrug linked to hydroxybupropion. <i>Journal of Controlled Release</i> , 2006, 113, 137-145.	9.9	42
65	LC-MS method for the estimation of δ^8 -THC and 11-nor- δ^8 -THC-9-COOH in plasma. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2005, 38, 112-118.	2.8	15
66	In vivo evaluation of 3-O-alkyl ester transdermal prodrugs of naltrexone in hairless guinea pigs. <i>Journal of Controlled Release</i> , 2005, 102, 509-520.	9.9	31
67	Bioconversion of Naltrexone and Its 3-O-Alkyl-Ester Prodrugs in a Human Skin Equivalent. <i>Journal of Pharmaceutical Sciences</i> , 2005, 94, 828-836.	3.3	23
68	Transdermal Delivery of Naltrexone and its Active Metabolite 6- β -Naltrexol in Human Skin in Vitro and Guinea Pigs in Vivo. <i>Journal of Pharmaceutical Sciences</i> , 2005, 94, 1965-1975.	3.3	30
69	Human Skin Permeation of Branched-Chain 3-O-Alkyl Ester and Carbonate Prodrugs of Naltrexone. <i>Pharmaceutical Research</i> , 2005, 22, 758-765.	3.5	29
70	In Vitro/in Vivo Correlation of Transdermal Naltrexone Prodrugs in Hairless Guinea Pigs. <i>Pharmaceutical Research</i> , 2005, 22, 981-989.	3.5	35
71	In Vitro Release Studies on Matrix Type Transdermal Drug Delivery Systems of Naltrexone and Its Acetyl Prodrug. <i>Drug Development and Industrial Pharmacy</i> , 2005, 31, 871-877.	2.0	20
72	A duplex α -Gemini α -prodrug of naltrexone for transdermal delivery. <i>Journal of Controlled Release</i> , 2004, 97, 283-290.	9.9	35

#	ARTICLE	IF	CITATIONS
73	Transdermal Delivery of the Synthetic Cannabinoid WIN 55,212-2: In Vitro/in Vivo Correlation. <i>Pharmaceutical Research</i> , 2004, 21, 1137-1145.	3.5	33
74	Physicochemical Evaluation, in Vitro Human Skin Diffusion, and Concurrent Biotransformation of 3-O-Alkyl Carbonate Prodrugs of Naltrexone. <i>Pharmaceutical Research</i> , 2004, 21, 1146-1152.	3.5	33
75	In vitro/in vivo correlation studies for transdermal 8 -THC development. <i>Journal of Pharmaceutical Sciences</i> , 2004, 93, 1154-1164.	3.3	35
76	Transdermal permeation of WIN 55,212-2 and CP 55,940 in human skin in vitro. <i>International Journal of Pharmaceutics</i> , 2004, 278, 173-180.	5.2	19
77	Liquid chromatographic-mass spectrometric quantitation of 9 -tetrahydrocannabinol and two metabolites in pharmacokinetic study plasma samples. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2004, 803, 243-248.	2.3	20
78	Intranasal Delivery of Recombinant Human Parathyroid Hormone [hPTH (1-34)], Teriparatide in Rats. <i>Endocrine Research</i> , 2004, 30, 455-467.	1.2	19
79	Development and validation of a liquid chromatography-mass spectrometry method for the quantitation of naltrexone and 2 -naltrexol in guinea pig plasma. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2004, 810, 259-267.	2.3	15
80	Development and validation of a liquid chromatography-mass spectrometry method for the quantitation of naltrexone and 2 -naltrexol in guinea pig plasma. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2004, 810, 259-267.	2.3	13
81	Xenobiotic bioconversion in human epidermis models. <i>Pharmaceutical Research</i> , 2003, 20, 1113-1118.	3.5	15
82	Straight-Chain Naltrexone Ester Prodrugs: Diffusion and Concurrent Esterase Biotransformation in Human Skin. <i>Journal of Pharmaceutical Sciences</i> , 2002, 91, 2571-2578.	3.3	62
83	In vitro experiment optimization for measuring tetrahydrocannabinol skin permeation. <i>International Journal of Pharmaceutics</i> , 2002, 241, 329-339.	5.2	48
84	Determining dermal absorption parameters in vivo from tape strip data. <i>Pharmaceutical Research</i> , 2002, 19, 292-298.	3.5	77
85	Chemical uptake into human stratum corneum in vivo from volatile and non-volatile solvents. <i>Pharmaceutical Research</i> , 1999, 16, 1288-1293.	3.5	73
86	Characterization of the permeability barrier of human skin <i>in vivo</i> . <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1997, 94, 1562-1567.	7.1	188
87	Transdermal Prodrug Concepts: Permeation of Buprenorphine and Its Alkyl Esters through Hairless Mouse Skin and Influence of Vehicles. <i>Biological and Pharmaceutical Bulletin</i> , 1996, 19, 263-267.	1.4	17
88	Permeation of buprenorphine and its 3-alkyl-ester prodrugs through human skin. <i>Pharmaceutical Research</i> , 1996, 13, 1519-1523.	3.5	38
89	A solubility and related physicochemical property comparison of buprenorphine and its 3-alkyl esters. <i>Pharmaceutical Research</i> , 1995, 12, 1526-1529.	3.5	21
90	The effects of ethanol and Ro 15-4513 on elevated plus-maze and rotarod performance in long-sleep and short-sleep mice. <i>Alcohol</i> , 1989, 6, 369-376.	1.7	25

#	ARTICLE	IF	CITATIONS
91	Further characterization of benzodiazepine receptor differences in long-sleep and short-sleep mice. Life Sciences, 1988, 43, 1223-1231.	4.3	32
92	Naloxone antagonism of hyperactivity in morphine-treated hamsters. Bulletin of the Psychonomic Society, 1987, 25, 482-485.	0.2	3
93	Advanced harmonization techniques result in accurate establishment of in vitroâ€œin vivo correlations for oxybenzone from four complex dermal formulations with reapplication. Drug Delivery and Translational Research, 0, , .	5.8	0